Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 362-374

  Sizemore, Donata R ^a,b   Warner, Elizabeth A ^a,c   Lawrence, Julie A ^a,d   Thomas, Lawrence J ^a   Roland, Kenneth L ^a,e   Killeen, Kevin P ^a,f  

^a Celldex Therapeutics Inc   (United Kingdom)

^b CRUCELL HOLLAND BV   (Netherlands)

^c MEDTRONIC INC   (United States)

^d Sequoia Sciences Inc   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f Matrivax Research and Development Corp   (United States)

Author keywords

F1 V; Immunogenicity; Plague; Salmonella typhimurium; Vaccine

Indexed keywords

BACTERIAL VACCINE; BACTERIAL VECTOR; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN V; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAF1 PROTEIN, YERSINIA PESTIS; LCRV PROTEIN, YERSINIA; LIVE VACCINE; PHOP PROTEIN, BACTERIA; PHOQ PROTEIN, BACTERIA; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEIN; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOPLASM; IMMUNOGENICITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLAGUE; PLASMID; SALMONELLA TYPHIMURIUM; VACCINE PRODUCTION; ANIMAL; BLOOD; GENE INACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM; RABBIT;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; GENE KNOCKOUT TECHNIQUES; MALE; MICE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RABBITS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

EID: 84860381502     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18670     Document Type: Article

References (40)

1. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al & Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. JAMA 2000; 283:2281-90; PMID:10807389; http://dx.doi.org/10.1001/jama.283.17.2281
2. Knight J. Delivering 2012 death in the mail. Nature 2001; 414:837-8; PMID:11780023; http://dx.doi.org/10.1038/414837a
3. Kotton CN, Hohmann EL. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun 2004; 72:5535-47; PMID:15385450; http://dx.doi.org/10.1128/IAI.72.10.5535-5547.2004
4. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009; 87:400-12; PMID:19417771; http://dx.doi.org/10.1038/icb. 2009.31
5. Atkins HS, Morton M, Griffin KF, Stokes MG, Nataro JP, Titball RW. Recombinant Salmonella vaccines for biodefence. Vaccine 2006; 24:2710-7; PMID:16434131; http://dx.doi.org/10.1016/j.vaccine.2005.12.046
6. Li B, Jiang L, Song Q, Yang J, Chen Z, Guo Z, et al. Protein microarray for profiling antibody responses to Yersinia pestis live vaccine. Infect Immun 2005; 73:3734-9; PMID:15908403; http://dx.doi.org/10.1128/IAI.73.6.3734-3739. 2005
7. Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, et al. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine 2006; 24:2477-90; PMID:16442673; http://dx.doi.org/10.1016/j.vaccine.2005.12.057
8. Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 2006; 24:1625-32; PMID:16243411; http://dx.doi.org/10.1016/j.vaccine.2005.09. 052
9. Santi L, Giritch A, Roy CJ, Marillonnet S, Klimyuk V, Gleba Y, et al. Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci U S A 2006; 103:861-6; PMID:16410352; http://dx.doi.org/10.1073/pnas.0510014103
10. Eyles JE, Elvin SJ, Westwood A, Lebutt CS, Alpar HO, Somavarapu S, et al. Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine 2004; 22:4365-73; PMID:15474730; http://dx.doi.org/10. 1016/j.vaccine.2004.02.049
11. Glynn A, Freytag LC, Clements JD. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 2005; 23:1957-65; PMID:15734068; http://dx.doi.org/10.1016/j.vaccine.2004.10.025
12. Glynn A, Roy CJ, Powell BS, Adamovicz JJ, Freytag LC, Clements JD. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 2005; 73:5256-61; PMID:16041052; http://dx.doi.org/10.1128/IAI.73.8.5256-5261. 2005
13. Kang HY, Srinivasan J, Curtiss R, 3rd. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun 2002; 70:1739-49; PMID:11895935; http://dx.doi.org/10.1128/IAI.70.4.1739-1749.2002
14. Gentschev I, Mollenkopf H, Sokolovic Z, Hess J, Kaufmann SH, Goebel W. Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 1996; 179:133-40; PMID:8955639; http://dx.doi.org/10. 1016/S0378-1119(96)00424-6
15. Cárdenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev 1992; 5:328-42; PMID:1498769
16. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408-14; PMID:8648213; http://dx.doi.org/10.1093/infdis/173.6.1408
17. Anonymous. (2008) AVANT's single-dose oral Ty800 vaccine meets primary endpoints in Phase 2 study, In Medical News Today.
18. Anderson GW, Jr., Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 1996; 64:4580-5; PMID:8890210
19. Calhoun LN, Kwon YM. Salmonella-based plague vaccines for bioterrorism. J Microbiol Immunol Infect 2006; 39:92-7; PMID:16604240
20. Williamson ED, Stagg AJ, Eley SM, Taylor R, Green M, Jones SM, et al. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague. Vaccine 2007; 25:1142-8; PMID:17101198; http://dx.doi.org/10. 1016/j.vaccine.2006.09.052
21. Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M, et al. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 2007; 178:1059-67; PMID:17202369
22. Curtiss R, 3rd, Xin W, Li Y, Kong W, Wanda SY, Gunn B, et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010; 30:255-70; PMID:20370633
23. Morton M, Garmory HS, Perkins SD, O'Dowd AM, Griffin KF, Turner AK, et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine 2004; 22:2524-32; PMID:15193377; http://dx.doi.org/10.1016/j.vaccine.2004.01.007
24. Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997; 65:1926-30; PMID:9125581
25. Garmory HS, Leckenby MW, Griffin KF, Elvin SJ, Taylor RR, Hartley MG, et al. Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect Immun 2005; 73:2005-11; PMID:15784541; http://dx.doi.org/10.1128/IAI.73.4.2005- 2011.2005
26. Spreng S, Dietrich G, Weidinger G. Rational design of Salmonella-based vaccination strategies. Methods 2006; 38:133-43; PMID:16414270; http://dx.doi.org/10.1016/j.ymeth.2005.09.012
27. Ryan ET, Crean TI, Kochi SK, John M, Luciano AA, Killeen KP, et al. Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun 2000; 68:221-6; PMID:10603391; http://dx.doi.org/10.1128/IAI.68.1. 221-226.2000
28. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68:2135-41; PMID:10722611; http://dx.doi.org/10. 1128/IAI.68.4.2135-2141.2000
29. Nakayama K, Kelly SM, Curtiss R. Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine Strain. Nat Biotechnol 1988; 6:693-7; http://dx.doi.org/10.1038/nbt0688-693
30. Oyston PC, Williamson ED, Leary SE, Eley SM, Griffin KF, Titball RW. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun 1995; 63:563-8; PMID:7822022
31. Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog 1997; 23:167-79; PMID:9281474; http://dx.doi.org/10.1006/mpat.1997.0141
32. Branger CG, Sun W, Torres-Escobar A, Perry R, Roland KL, Fetherston J, et al. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge. Vaccine 2010; 29:274-82; PMID:20979987; http:// dx.doi.org/10.1016/j.vaccine.2010.10.033
33. Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007; 25: 8574-84; PMID:18045752; http://dx.doi.org/ 10.1016/j.vaccine.2007.09.074
34. Linnetz EG, Borrelli KM, Mazzolla AM, Ryan GS, Sikes KB, Kearney MA, et al. Optimization of a rabbit model of attenuated Vibrio cholerae immunogenicity. Contemporary Topics 2004; 43:58.
35. Roland KL, Tinge SA, Kochi SK, Thomas LJ, Killeen KP. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine 2010; 28:3679-87; PMID: 20338215; http://dx.doi.org/10.1016/j.vaccine.2010.03.019
36. Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol 2007; 14:605-16; PMID:17376861; http://dx.doi.org/10.1128/CVI.00398-06
37. Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, et al. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb Pathog 2007; 42:11-21; PMID:17107769; http://dx.doi.org/10.1016/j.micpath.2006.09.003
38. Sizemore DR, Warner B, Lawrence J, Jones A, Killeen KP. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine 2006; 24:3793- 803; PMID:16135393; http://dx.doi.org/10.1016/j.vaccine.2005.07.026
39. Wai SN, Westermark M, Oscarsson J, Jass J, Maier E, Benz R, et al. Characterization of dominantly negative mutant ClyA cytotoxin proteins in Escherichia coli. J Bacteriol 2003; 185:5491-9; PMID:12949101; http://dx.doi.org/10.1128/JB.185.18.5491-5499.2003
40. Carlone GM, Thomas ML, Rumschlag HS, Sottnek FO. Rapid microprocedure for isolating detergentinsoluble outer membrane proteins from Haemophilus species. J Clin Microbiol 1986; 24:330-2; PMID:3489731